Adjuvant Tebentafusp in High Risk Ocular Melanoma

At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in patients with metastatic uveal melanoma in a randomized trial. Based on the results in the advanced setting, it is hypothesized that treatment with tebentafusp may reduce the risk of development of disease recurrence.

Trial Details

NCT ID
NCT06246149
Phase
PHASE3
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Tebentafusp
Locations (sample)
  • Lake Success, New York, United States|40.77066,-73.71763
  • Brussels, Belgium|50.85045,4.34878
  • Nice, France|43.70313,7.26608
  • Paris, France|48.85341,2.3488
  • Berlin, Germany|52.52437,13.41053

Key Eligibility Criteria

  • Primary non-metastatic UM, except iris melanoma, after definitive treatment either by surgery or radiotherapy
  • Time from primary treatment smaller than 11 weeks (note that the maximum time between primary treatment and randomization is 12 weeks )
  • High-risk according to either 1) clinical criteria: TNM (AJCC8) stage III or 2) genetic criteria: monosomy 3 or GEP class 2. Prior to enrolment of …
  • ECOG performance status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →